The number of potential pediatric heart transplant recipients continues to exceed the number
of donors, and consequently the waitlist mortality remains significant. Despite this, around …

Background and aims The Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension
(TOPP) registry is a global network established to gain insights into the disease course …

Pulmonary arterial hypertension (PAH) develops in 5–10% of patients with congenital heart
disease (CHD) [1], and PAH associated with congenital heart disease (PAH-CHD) accounts …

Angiotensin-converting enzyme inhibitors (ACEI), such as enalapril, are a cornerstone of
treatment for pediatric heart failure which is still used off-label. Using a novel age-appropriate …

Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with
pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of …

Introduction Treatment of paediatric heart failure is based on paradigms extensively tested
in the adult population assuming similar underlying pathophysiological mechanisms. …

Background The occurrence of postoperative chylothorax in children with congenital heart
disease is a rare and serious complication in cardiac intensive care units (ICUs). The aim of …

Early stages of chronic kidney disease (CKD) are often underdiagnosed, while their deleterious
effects on the cardiovascular (CV) system are already at work. Thus, the assessment of …

PAH is a progressive life‐threatening disease in children. While parenteral prostacyclin
therapy improves survival in patients with severe PAH , central line‐related complications are …

BACKGROUND The therapeutic success in patients with congenital heart disease (CHD)
leads to a growing number of adults with CHD (adult CHD [ACHD]) who develop end-stage …